Human Mesenchymal glioblastomas are characterized by an increased immune cell presence compared to Proneural and Classical tumors

Authors: Ioannis Kaffes, Frank Szulzewsky, Zhihong Chen, Cameron J. Herting, Ben Gabanic, José E. Velázquez Vega, Jennifer Shelton, Jeffrey M. Switchenko, James Ross, Leon McSwain, Jason T. Huse, Bengt Westermark, Sven Nelander, Karin Forsberg‐Nilsson, Lene Uhrbom, Naga Prathyusha Maturi, Patrick J. Cimino, Eric C. Holland, Helmut Kettenmann, Cameron Brennan, Daniel J. Brat, Dolores Hambardzumyan - OncoImmunology 2019 cited by 165

, which encodes the TAM-specific protein IBA1, correlated with a worse prognosis in Proneural GBM, but conferred a survival benefit in Mesenchymal tumors. We used our data to construct a mathematical model that could reliably identify Mesenchymal GBM with high sensitivity using a combination of the aforementioned cell-specific IHC markers. In conclusion, we demonstrated that molecularly distinct GBM subtypes are characterized by profound differences in the composition of their immune microenvironment, which could potentially help to identify tumors amenable to immunotherapy.